TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10220224
Drug: Immunocytochemistry with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunocytochemistry with antibodies recognizing NR1 or NR2A/B subunits
Study: 7787130
Drug: Dolasetron mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesylate, single IV doses ranging from 0.30 to 0.60 mg kg‐1 on day 1
Study: 7787130
Drug: Dolasetron mesylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesylate, multiple IV doses ranging from 0.60 to 1.20 mg kg‐1 d‐1 on days 2-9
Study: 381954
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 50 mg once or twice daily
Study: 23811305
Drug: HIGH-dose steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGH-dose steroid (prednisolone 5mg/kg/day, n=44)
Study: 23811305
Drug: Steroids (LOW-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (LOW-dose and HIGH-dose)
Study: 17905421
Drug: Bortezomib 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 0.8 mg/m2 with carboplatin
Study: 1728731
Drug: Preoperative antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotics
Study: 8443934
Drug: Flurbiprofen 100
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 100 mg twice daily
Study: 3976820
Drug: Activity therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activity therapy (n = 7)
Study: 3976820
Drug: Verbal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal therapy (n = 6)
Study: 3976820
Drug: Normal milieu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal milieu therapy (control group, n = 6)
Study: 26103919
Drug: Regular home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular home visits (treatment group)
Study: 19019888
Drug: Tocilizumab monotherapy
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab monotherapy (8 mg/kg every 4 weeks)
Study: 10686224
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 microg every 3 h for a maximum of five doses in 24 h
Study: 10686224
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 400 microg every 6 h for a maximum of three doses in 24 h
Study: 3581491
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg betahistine
Study: 3581491
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg betahistine
Study: 9349857
Drug: 64 mg
Normalized name: sulfur 64 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 mg betahistine
Study: 2899660
Drug: azathioprine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: azathioprine 2.5 mg/kg daily
Study: 29799915
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo or alternative treatment not specified)
Study: 31980883
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy and medicament therapy (group 1)
Study: 27305912
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg PO daily
Study: 26549714
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate 120 mg
Study: 16204903
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5% lignocaine and 0.5% minoxidil
Study: 12432838
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti‐Helicobacter pylori antibodies (anti‐HP Ab) in women with vomiting (162 women)
Study: 12432838
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of anti‐Helicobacter pylori antibodies (anti‐HP Ab) in women with severe emesis (250 women)
Study: 10707114
Drug: Ibuprofen with
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen with diazepam administered at 22.00 hours
Study: 10707114
Drug: Ibuprofen alone
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen alone administered at 22.00 hours
Study: 1361068
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 micrograms twice daily
Study: 2540650
Drug: Isradipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (2.5 mg twice daily)
Study: 27893068
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of the 9-valent HPV vaccine (6 months apart)
Study: 27893068
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of the 9-valent HPV vaccine (12 months apart)
Study: 27893068
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of the 9-valent HPV vaccine (6 months apart)
Study: 18500518
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg p.o. alone
Study: 24170263
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg p.o. with 4,000 mg calcium carbonate (Tums Ultra) administered 15 min before
Study: 9841760
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r‐HuEPO) 300 IU/kg on day 4 before surgery and 150 IU/kg daily for 7 days
Study: 27776598
Drug: Complex second-line
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex second-line treatment (control)
Study: 24317232
Drug: SPEDI technique
Normalized name: benzalkonium chloride Topical Powder [Pedi-Pro]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPEDI technique (15 mL of ropivacaine 0.75% around the sciatic nerve and 5 mL of ropivacaine 0.75% at the saphenous nerve)
Study: 16051910
Drug: Consumer-directed care
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumer-directed care (treatment group)
Study: 1791078
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefotaxime i.v. plus 200 mg ofloxacin twice daily (group 1)
Study: 1791078
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefotaxime i.v. twice daily plus tobramycin i.v. three times daily (group 2)
Study: 21350928
Drug: Triazolam (0.12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.12 mg/70 kg) + Progesterone (100 mg)
Study: 19628958
Drug: Individual narrative
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual narrative exposure therapy (NET, n=12)
Study: 7886971
Drug: molsidomin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: molsidomin (2 mg)
Study: 7886971
Drug: ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (8 mg)
Study: 7886971
Drug: molsidomin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: molsidomin (2 mg) and ondansetron (8 mg)
Study: 31856771
Drug: Preventive Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive Cognitive Therapy (PCT)
Study: 20386359
Drug: Gene-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene-based dosing algorithm
Study: 20386359
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care dosing
Study: 14763702
Drug: Daily pin
Normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pin site care (n = 27)
Study: 14763702
Drug: Weekly pin
Normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly pin site care (n = 23)
Study: 10808698
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CYFRA 21-1 and CEA
Study: 21788248
Drug: Magnetic field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic field therapy
Study: 6181331
Drug: Standard amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard amitriptyline (75 mg)
Study: 6181331
Drug: Sustained-release amitriptyline
Normalized name: amitriptyline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release amitriptyline (75 mg)
Study: 6181331
Drug: Sustained-release amitriptyline
Normalized name: amitriptyline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release amitriptyline
Study: 31535806
Drug: Silodosin (monotherapy)
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin (monotherapy)
Study: 26656144
Drug: Persistently high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistently high sST2 levels (>60 ng/ml) at follow-up
Study: 23017309
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (4 capsules daily for 8 weeks, each containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Study: 17620054
Drug: 0.014 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.014 mg/d transdermal estradiol patch
Study: 29077146
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (45 patients)
Study: 29077146
Drug: Large rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large rosuvastatin dose group (47 patients, 20 mg/d)
Study: 25355194
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg once daily
Study: 15906586
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg once daily
Study: 19223284
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg OA cohort
Study: 19223284
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg OA cohort
Study: 15334426
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg twice daily
Study: 11739476
Drug: Intravenous ghrelin
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ghrelin (5.0 pmol/kg/min)
Study: 2435738
Drug: Intra-arterial prostacyclin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial prostacyclin infusion
Study: 29644962
Drug: Curcumin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (400 mg/kg)
Study: 17179687
Drug: Tolterodine (To,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (To, 2 mg twice daily)
Study: 17179687
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Bladder Training and Tolterodine (Co)
Study: 8324274
Drug: 0.15% podophyllotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% podophyllotoxin cream
Study: 3706190
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of pyridoxine X HCl
Study: 22803768
Drug: Monthly oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly oral ibandronate 150 mg
Study: 7875147
Drug: GM‐CSF (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF (60 micrograms/m2) with antibiotics (ticarcillin‐clavulanate plus netilmicin)
Study: 30711184
Drug: Acetaminophen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1000 mg) and Ibuprofen (600 mg)
Study: 12889783
Drug: 500‐mg clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500‐mg clarithromycin tablet (Test formulation)
Study: 12889783
Drug: 500‐mg clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500‐mg clarithromycin tablet (Reference formulation)
Study: 9378847
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg every 12 hours
Study: 29851803
Drug: Laser acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser acupuncture (LA) plus conventional treatment
Study: 31725787
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy
Study: 27622897
Drug: DA alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA alginate antacid
Study: 20329658
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg (test product)
Study: 20329658
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg (reference product)
Study: 18446589
Drug: Albuterol pMDI
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol pMDI 90 microg x 2 inhalations (180 microg)
Study: 10889800
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss as a treatment
Study: 10889800
Drug: Routine clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine clinical practice treatments
Study: 8783687
Drug: 1 rejection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 rejection treatment
Study: 8783687
Drug: 2 rejection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 rejection treatments
Study: 8783687
Drug: >= 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: >= 3 rejection treatments
Study: 1731541
Drug: 3 micrograms/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 micrograms/mL buprenorphine with 0.015% bupivacaine and 1 microgram/mL epinephrine
Study: 1731541
Drug: 3 micrograms/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 micrograms/mL fentanyl with 0.015% bupivacaine and 1 microgram/mL epinephrine
Study: 19996349
Drug: Inhaled mannitol
Normalized name: mannitol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mannitol alone
Study: 19996349
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mannitol and rhDNase
Study: 16083518
Drug: Zolmitriptan orally
Normalized name: Zolmitriptan Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan orally disintegrating tablet (ODT)
Study: 2576246
Drug: Bunazosin hydrochloride
Normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin hydrochloride (morning dosage)
Study: 2576246
Drug: Bunazosin hydrochloride
Normalized name: bunazosin hydrochloride
DrugBank: Bunazosin (DB12230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bunazosin hydrochloride (evening dosage)
Study: 551922
Drug: Specific hypotensive
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific hypotensive therapy
Study: 12375675
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific treatment
Study: 30204517
Drug: Casein protein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein protein (CP) 40 g presleep
Study: 30204517
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) 40 g carbohydrates presleep
Study: 26083409
Drug: Lipid-based nutritional
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutritional supplement with additional vitamins and minerals
Study: 26083409
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Lipid-based nutritional supplement without additional vitamins and minerals)
Study: 19293261
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (5 or 10 g/d) plus GH (0, 3, or 5 microg/kg . d) for 16 weeks
Study: 9213289
Drug: Conventional antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antipsychotic medications
Study: 6738652
Drug: Theophylline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (mean plasma level, 13 +/- 2 mg per liter) after 7 days
Study: 31162568
Drug: Neladenoson 5
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neladenoson 5 mg
Study: 31162568
Drug: Neladenoson 10
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neladenoson 10 mg
Study: 31162568
Drug: Neladenoson 20
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neladenoson 20 mg
Study: 31162568
Drug: Neladenoson 30
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neladenoson 30 mg
Study: 31162568
Drug: Neladenoson 40
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neladenoson 40 mg
Study: 24483103
Drug: Compound Biejia
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Biejia Ruangan Tablet (CBRT)
Study: 24189463
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other anti-hypertensive drugs)
Study: 11113218
Drug: rt-PA treatment
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA treatment within 91 to 180 minutes
Study: 3324838
Drug: Intramuscular premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular premedication with 0.12 mg.kg‐1 midazolam and 0.5 mg atropine
Study: 20603243
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of Life Therapy (QOLT)
Study: 25307976
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no glucocorticoid treatment)
Study: 22561417
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine physical therapy)
Study: 12468136
Drug: Intracervical injection
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical injection of 5 ml mepivacaine 2%
Study: 6786796
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate nasal spray
Study: 12952117
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) nasal spray
Study: 22584174
Drug: Pinnacle3 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pinnacle3 treatment planning system using CCCS algorithm
Study: 16205134
Drug: DuraPrep solution
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuraPrep solution plus Ioban 2 drapes
Study: 2101781
Drug: Thrombolysis followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thrombolysis followed by oral captopril on day 3-4 (35 patients)
Study: 9691229
Drug: Pyrazinoylguanidine (PZG),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrazinoylguanidine (PZG), 400 mg three times a day for 3 weeks
Study: 3395403
Drug: Vadocaine hydrochloride
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vadocaine hydrochloride 10 mg
Study: 3395403
Drug: Vadocaine hydrochloride
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vadocaine hydrochloride 30 mg
Study: 3395403
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate 50 mg
Study: 12144585
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg t.d.s.
Study: 10930898
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg b.d. (after 2 weeks of placebo or cisapride 10 mg t.d.s.)
Study: 8800872
Drug: Sodium ironedetate
Normalized name: Sodium ironedetate
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ironedetate (Sytron) administered rectally at a concentration of 7.6 mg ml‐1
Study: 1353804
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 plus 750 mg/m2 cyclophosphamide (high dose)
Study: 1353804
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m2 plus 750 mg/m2 cyclophosphamide (low dose)
Study: 22820371
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (25‐hydroxy vitamin D); specific dosage and duration not mentioned.
Study: 2459525
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg/day)
Study: 11181473
Drug: Endothelin A
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin A receptor blocker LU 135252 (30 mg/d)
Study: 11181473
Drug: Endothelin A
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin A receptor blocker LU 135252 (300 mg/d)